Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis
- PMID: 26589610
- DOI: 10.1007/s11255-015-1161-3
Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis
Abstract
Background: It is controversial whether chromophobe renal cell carcinoma (chRCC) or clear cell renal cell carcinoma (ccRCC) is associated with better survival. We conducted a clinical-based cohort study and meta-analysis to evaluate the prognostic role of histology between chRCC and ccRCC.
Methods: A cohort of 1540 patients (166 with chRCC and 1374 with ccRCC) were selected from Sun Yat-sen University and The Cancer Genome Atlas databases. The clinicopathological parameters and overall survival (OS) were compared between patients with chRCC and those with ccRCC. For the meta-analysis, we searched the PubMed, Cochrane Library, and Ovid databases for studies comparing OS or cancer-specific survival (CSS) between chRCC and ccRCC.
Results: The cohort study revealed that patients with chRCC were younger (median 52 vs. 55 years, P < 0.001), were more commonly female (47.0 vs. 33.0%, P < 0.001), and had a larger tumor size (mean 7.1 vs. 5.9 cm, P < 0.001), and they had a lower stage compared with those with ccRCC. Five-year OS rates for chRCC and ccRCC were 90.3 and 75.3%, respectively (P < 0.001). We found significantly better survival for chRCC in stratification analysis by age, sex, tumor size, and stage. Similar results were observed on both univariate [hazard ratio (HR), 0.30; 95% confidence interval (CI) 0.16-0.55, P < 0.001] and multivariate analyses (HR 0.42; 95% CI 0.23-0.79, P = 0.006). Ten studies were included in our meta-analysis. Eight of them provided data on univariate analysis. The pooled HR was statistically significant for OS (pooled HR 0.49; 95% CI 0.30-0.79, P = 0.004) and CSS (pooled HR 0.49; 95% CI 0.37-0.64, P < 0.001). Seven studies reported the HR on multivariate analysis. The pooled HR was also statistically significant for OS (pooled HR 0.63; 95% CI 0.51-0.77, P < 0.001) and CSS (pooled HR 0.72; 95 % CI 0.57-0.90, P = 0.003). These data indicate that patients with chRCC had better outcomes than those with ccRCC.
Conclusions: Our large cohort study and meta-analysis confirmed that chRCC had better survival than ccRCC.
Keywords: Chromophobe renal cell carcinoma; Clear cell renal cell carcinoma; Survival.
Similar articles
-
Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1. BJU Int. 2012. PMID: 22044519
-
Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.Virchows Arch. 2014 Oct;465(4):439-44. doi: 10.1007/s00428-014-1648-9. Epub 2014 Sep 2. Virchows Arch. 2014. PMID: 25178561
-
Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.Urol Oncol. 2019 Oct;37(10):727-734. doi: 10.1016/j.urolonc.2019.05.008. Epub 2019 Jun 5. Urol Oncol. 2019. PMID: 31174958
-
The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis.Int Urol Nephrol. 2017 Jun;49(6):975-981. doi: 10.1007/s11255-017-1548-4. Epub 2017 Mar 7. Int Urol Nephrol. 2017. PMID: 28271326 Free PMC article. Review.
-
The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.Urol Oncol. 2021 Jul;39(7):422-430. doi: 10.1016/j.urolonc.2021.02.026. Epub 2021 Apr 29. Urol Oncol. 2021. PMID: 33934963
Cited by
-
Renal cell carcinoma histological subtype distribution differs by age, gender, and tumor size in coastal Chinese patients.Oncotarget. 2017 May 16;8(42):71797-71804. doi: 10.18632/oncotarget.17894. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069747 Free PMC article.
-
Localized chromophobe renal cell carcinoma: preoperative imaging judgment and laparoscopic simple enucleation for treatment.Int Braz J Urol. 2018 Sep-Oct;44(5):922-932. doi: 10.1590/S1677-5538.IBJU.2017.0519. Int Braz J Urol. 2018. PMID: 29757571 Free PMC article.
-
Nomograms-based prediction of overall and cancer-specific survivals for patients with chromophobe renal cell carcinoma.Exp Biol Med (Maywood). 2021 Mar;246(6):729-739. doi: 10.1177/1535370220977107. Epub 2020 Dec 10. Exp Biol Med (Maywood). 2021. PMID: 33302735 Free PMC article.
-
Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022.Curr Oncol Rep. 2022 Sep;24(9):1201-1208. doi: 10.1007/s11912-022-01269-1. Epub 2022 Apr 19. Curr Oncol Rep. 2022. PMID: 35438388 Free PMC article. Review.
-
Prognostic Value of Clinical and Pathological Features in Chinese Patients with Chromophobe Renal Cell Carcinoma: A 10-Year Single-Center Study.J Cancer. 2017 Sep 27;8(17):3474-3479. doi: 10.7150/jca.19953. eCollection 2017. J Cancer. 2017. PMID: 29151931 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical